公开(公告)号：US20150191495A1

公开(公告)日：2015-07-09

申请号：US14418147

申请日：2013-07-31

Applicant: Merck Sharp & Dohme Corp.

Inventor： William K. Hagmann ,  Ravi P. Nargund ,  Timothy A. Blizzard ,  Hubert Josien ,  Purakkattle Biju ,  Christopher W. Plummer ,  Qun Dang ,  Bing Li ,  Derun Li ,  Linus S. Lin ,  Mingxiang Cui ,  Bin Hu ,  Jinglai Hao ,  Zhengxia Chen

IPC: C07F9/58 ,  A61K31/4427 ,  C07D221/16 ,  A61K31/4412 ,  C07D401/12 ,  A61K31/444 ,  A61K31/4433 ,  C07D409/14 ,  A61K31/513 ,  C07D417/12 ,  A61K31/4439 ,  C07D401/14 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/675 ,  A61K45/06 ,  C07D405/12

CPC classification number: C07F9/58 ,  A61K31/435 ,  A61K31/4412 ,  A61K31/4427 ,  A61K31/4433 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K31/5377 ,  A61K31/675 ,  A61K45/06 ,  C07D221/16 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D409/14 ,  C07D417/12

Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Abstract translation: 结构式（I）的新型化合物及其药学上可接受的盐是G蛋白偶联受体40（GPR40）的激动剂，可用于治疗，预防和抑制G蛋白偶联受体 受体40.本发明的化合物可用于治疗2型糖尿病，以及通常与该疾病相关的病症，包括肥胖症和脂质疾病，例如混合或糖尿病性血脂异常，高脂血症，高胆固醇血症和 高甘油三酯血症